ICU Medical (ICUI) investor relations material

Company evolution and strategic positioning

• Transitioned from an OEM supplier to a global pure-play infusion company through acquisitions and divestitures.

• Focuses on new technology in a consolidated market, offering global reach and investor-friendly risk-reward.

• Demonstrated earnings growth and improved capital allocation by moving capital-intensive IV Solutions into a joint venture.

• Product portfolio is positioned for growth due to market consolidation and innovation.

Consumables segment insights

• Core consumables business (~$1B) includes infusion therapy, oncology, vascular access, and tracheostomy products.

• Legacy infusion therapy and oncology have grown 5–7% annually, driven by pricing, niche markets, and pump wins.

• Price increases are expected to return in 2025 and escalate further in 2027 due to contract structures.

• Growth is supported by clinical differentiation, economic leverage in deals, and international opportunities.

• New product innovation focuses on oncology, dialysis, and custom IV sets, with future expansion in vascular access and subcutaneous delivery.

Infusion systems and technology

• Full portfolio now includes LVP, ambulatory, and syringe pumps, with market share gains from aging competitor devices.

• Newer products (Plum Duo and Solo) address market needs for multiplexing and user-friendly design.

• Regulatory clearance for new syringe and ambulatory pumps is progressing, with integration into customer roadmaps.

• LifeShield software unifies drug libraries across modalities, offers cloud deployment, and enables future analytics and subscription revenue.

• Interoperability is a key market trend, with only ~20% U.S. penetration but expected to become standard over the next decade.